Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...
Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to ...
The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.
The Food and Drug Administration on Thursday approved Journavx, a non-opioid painkiller that is the first novel pain drug to win government authorization in more than 20 years. Vertex ...
The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.
The FDA's approval of the non-addictive painkiller Journavx last week marked a milestone in the field of pain management. Why ...
For the first time in more than 25 years, the U.S. Food and Drug Administration has signed off on a new type of pain reliever ...
H.C. Wainwright analyst Andrew Fein increased the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $550 from the previous $535, while maintaining a Buy rating on the stock.
The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...
The Food and Drug Administration (FDA) is hoping a newly approved non-opioid pain medication could help save lives. Dr.
While it's next to impossible to know how many opioids entered the state illegally in 2023, we do know that just under 1.7 ...